Advertisement

Advertisement

Lung Cancer

STAS Predicts Prognosis in Early NSCLC Regardless of Surgical Approach

The presence of tumor spread through air spaces (STAS) demonstrated an association with poor prognosis in patients with early-stage non–small cell lung cancer (NSCLC), whether undergoing segmentectomy or lobectomy, according to findings from an analysis of the phase III JCOG0802/WJOG4607L trial...

Lung Cancer

Hypofractionated Radiotherapy Plus Concurrent Chemotherapy vs Conventional Radiotherapy in Phase III Trial for LS-SCLC

A reduced schedule for hypofractionated radiotherapy with concurrent chemotherapy led to numerically similar survival outcomes and a more favorable safety profile compared with a standard course of conventional fractionated radiotherapy for patients with limited-stage small cell lung cancer...

Lung Cancer

Tarlatamab and Anti–PD-1 Therapy as First-Line Maintenance for ES-SCLC

The DLL3-targeted bispecific T-cell engager agent tarlatamab demonstrated significant overall survival in combination with anti‒PD-L1 therapy of either atezolizumab or durvalumab as first-line maintenance therapy for patients with extensive-stage small cell lung cancer (ES-SCLC), according to...

Lung Cancer

New Subcutaneous Amivantamab Combo Dosing Schedule Shows Promising Safety and Efficacy in EGFR-Positive NSCLC

The combination of subcutaneous amivantamab-vmjw every 4 weeks plus daily oral lazertinib led to a high response rate in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to findings from an analysis of cohort 5 of the PALOMA-2 trial presented at ...

lung cancer

Jonathan Spicer, MD, PhD, on Perioperative Immunotherapy for Resectable NSCLC: HRQoL Outcomes

Jonathan D. Spicer, MD, PhD, of McGill University Health Centre, discusses health-related quality of life (HRQoL) findings from the CheckMate 77T trial. The analysis determined that receipt of perioperative nivolumab does not result in worse HRQoL outcomes vs placebo in patients with resectable non–small cell lung cancer (NSCLC), regardless of nodal status (Abstract MA04.05).

Lung Cancer

Novel Targeted Agent Under Study in MTAP-Deleted NSCLC

BMS-986504, a first-in-class agent targeting MTAP, demonstrated antitumor activity in heavily pretreated patients with MTAP-deleted non–small cell lung cancer (NSCLC), according to findings from the phase I/II CA240-0007 trial presented at the International Association for the Study of Lung Cancer...

Lung Cancer

Overall Survival Risk for VATS vs Open Lobectomy for Early Lung Cancer

Video-assisted thoracoscopic surgery (VATS) led to a 21% reduction in the risk of death compared with open lobectomy for patients with early-stage lung cancer, in a meta-analysis of randomized trials comparing the two approaches. Results of the meta-analysis were presented at the International...

Lung Cancer

Lung Cancer Screening May Benefit Adults Up to Age 80 Who Are Fit for Surgery

Older individuals up to the age of 80 who are eligible for lung surgery may achieve a survival benefit from lung cancer screening comparable to that for younger patients, according to the results of a multicenter cohort study from the United Kingdom presented at the International Association for...

Lung Cancer

No OS Benefit for Concurrent and Consolidative Durvalumab vs Consolidation Alone in Unresectable Stage III NSCLC

Treating patients who have stage III non–small cell lung cancer (NSCLC) with durvalumab concurrently with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival (OS) compared with consolidation therapy with durvalumab alone, according to research presented...

Lung Cancer

Adjuvant Chemoimmunotherapy for Resected Stage IB–IIIA NSCLC

Interim results from the phase III NADIM ADJUVANT trial, led by the Spanish Lung Cancer Group, suggest that adjuvant chemoimmunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non–small cell lung cancer (NSCLC) while maintaining an acceptable safety...

lung cancer

John M. Varlotto, MD, on Concurrent and Consolidation Durvalumab for Unresectable Stage III NSCLC

John M. Varlotto, MD, presents results from the phase III EA5181 trial (from the ECOG-ACRIN Cancer Research Group), which evaluated concurrent and consolidation durvalumab vs consolidation durvalumab alone for patients with unresectable stage III non–small cell lung cancer (NSCLC) (Abstract PL03.04). 

lung cancer

Jordi Remon, MD, PhD, on Aumolertinib Plus Chemotherapy in EGFR-Mutated NSCLC

Jordi Remon, MD, PhD, of Gustave Roussy, was the invited discussant for the phase III ACROSS 2 study (Abstract PL02.06). Dr. Remon describes the effect of the addition of aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor, to platinum/pemetrexed chemotherapy in patients with non–small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor-suppressor gene mutations. 

Lung Cancer

DLL3-Targeted Antibody-Drug Conjugate in Relapsed SCLC

A first-in-human phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate, demonstrated manageable safety and early signs of antitumor activity in patients with relapsed small cell lung cancer (SCLC). The results were presented at the International...

Lung Cancer

Previously Treated ES-SCLC: I-DXd Demonstrates High Response Rate

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody-drug conjugate, according to data presented at the International Association for the Study of Lung Cancer...

Lung Cancer
Immunotherapy

Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options

ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...

Lung Cancer

Aumolertinib Plus Chemotherapy Improves PFS in NSCLC With EGFR and Concomitant Tumor Suppressor Genes

New results from the phase III ACROSS 2 trial demonstrated that aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), combined with platinum-pemetrexed chemotherapy significantly improved progression-free survival (PFS) compared with aumolertinib monotherapy in patients with...

Lung Cancer

Zidesamtinib Demonstrates Responses in ROS1-Positive NSCLC

Treatment with the next-generation ROS1 tyrosine kinase inhibitor (TKI) zidesamtinib led to antitumor activity in patients with ROS1-positive non‒small cell lung cancer (NSCLC) who had experienced disease progression on prior TKI treatments. These findings from the phase I/II ARROS-1 trial were...

Lung Cancer

Izalontamab Brengitecan Plus Osimertinib Shows Activity in First-Line EGFR-Mutant NSCLC

The novel antibody-drug conjugate izalontamab brengitecan (also referred to as iza-bren, BL-B01D1) in combination with osimertinib induced a response in all patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and EGFR-sensitizing mutations treated with the combination in ...

Lung Cancer

Novel ADC Shows Promising Efficacy in Previously Treated EGFR-Mutated NSCLC

The first-in-class EGFR × HER3 bispecific antibody-drug conjugate izalontamab brengitecan (also referred to as iza-bren; BL-B01D1) demonstrated promising efficacy results plus a manageable safety profile in the treatment of patients with previously treated EGFR-mutated non–small cell lung cancer...

Lung Cancer

Observation Outperforms Adjuvant Crizotinib for Resected ALK-Positive NSCLC

Adjuvant treatment with the first-generation ALK inhibitor crizotinib failed to improve disease-free survival outcomes over observation for patients with surgically resected ALK-positive non–small cell lung cancer (NSCLC), according to findings from the phase III E4512 trial presented at the...

Lung Cancer

EGFR-Mutated NSCLC: Continuing Osimertinib Plus Chemotherapy Through Disease Progression Improves PFS

A new analysis from the COMPEL trial showed that patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who experienced non–central nervous system (CNS) disease progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based...

Lung Cancer

CheckMate 77T: Nivolumab Maintains Quality of Life and Reduces Symptom Deterioration in Resectable NSCLC

An analysis from the phase III CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non–small cell lung cancer (NSCLC), including those with stage III N2 disease. These results were presented at the...

Lung Cancer

Adagrasib vs Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C–Mutated NSCLC

As reported in The Lancet by Barlesi et al, the phase III KRYSTAL-12 trial has shown a significant progression-free survival benefit with adagrasib over docetaxel in patients with previously treated locally advanced or metastatic KRAS G12C–mutated non–small cell lung cancer (NSCLC). Study Details...

Lung Cancer

Neoadjuvant Osimertinib in the Perioperative Setting for Resectable, EGFR-Mutated NSCLC

“Neoadjuvant treatment with osimertinib, with or without chemotherapy, should be considered when planning treatment for patients with resectable, EGFR-mutated, stage II to IIIB non–small cell lung cancer [NSCLC],” according to Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and ...

Lung Cancer

Effect of Hippocampal Avoidance in Prophylactic Cranial Irradiation in SCLC

In a phase II/III trial (NRG-CC003) reported in the Journal of Clinical Oncology, Gondi et al found that hippocampal avoidance (HA) in prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) did not improve delayed recall failure but was associated with benefits in...

Lung Cancer

Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update

ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...

Lung Cancer

A Diagnosis of Stage IV Lung Cancer at 18 Has Tested My Faith—and Made It Stronger

The main symptom that eventually led to my diagnosis of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) started in the fall of 2009. I was just 17 and in my freshman year at college when I began experiencing a persistent cough. The coughing became so unrelenting over the next month, I...

Lung Cancer

Personalizing First-Line Therapy in NSCLC: Plasma-Guided Adaptive Treatment Approach

In patients with newly diagnosed, PD-L1–positive, advanced non–small cell lung cancer (NSCLC) who tested negative for driver mutations, implementation of plasma-guided treatment intensification—from monotherapy with the PD-1 inhibitor pembrolizumab to platinum doublet chemotherapy plus...

Lung Cancer

Web Tool Seeks to Reduce State Lung Cancer Mortality Rates

Experts from the National Lung Cancer Roundtable have created a customizable, web-based platform that allows groups and local leaders to develop state-based action plans for reducing lung cancer mortality rates. The platform, called the SBI Planning Tool, allows users to explore real-world...

Lung Cancer

Kinase Inhibitor Approved for Nonsquamous NSCLC With HER2 TKD–Activating Mutations

Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD)–activating mutations, as...

Lung Cancer

Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer

In patients with small cell lung cancer, second-line treatment with the bispecific T-cell engager tarlatamab-dlle (which targets the delta-like ligand 3 [DLL3]) vs standard-of-care chemotherapy appeared to significantly improve overall survival, progression-free survival, and patient-reported...

Lung Cancer

Ultraprocessed Food Consumption May Be Linked to Increased Lung Cancer Risk

Greater consumption of ultraprocessed food is associated with an increased risk of developing either small cell or non–small cell lung cancer, according to findings published in Thorax.  "Over the past 2 decades, the consumption of ultraprocessed food has significantly increased worldwide,...

Lung Cancer

Updated CHEST Guidelines Emphasize Minimally Invasive Surgery for Early-Stage NSCLC

Updated clinical guidelines for the management of patients with early-stage non–small cell lung cancer (NSCLC) from the American College of Chest Physicians (CHEST) recommend use of more minimally invasive procedures and methods where possible. The guidelines, published in the journal CHEST,...

Lung Cancer

Extended Outcomes With Addition of Sugemalimab to First-Line Chemotherapy in Metastatic NSCLC

In a 4-year follow-up of the Chinese phase III GEMSTONE-302 trial reported in The Lancet Oncology, Zhou et al examined the survival benefit of adding the PD-L1 inhibitor sugemalimab to first-line platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC) with no...

Lung Cancer

Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options

ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...

Lung Cancer

Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update

ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...

Lung Cancer

Patients With Interstitial Lung Disease Face Elevated Lung Cancer Risk, Study Finds

A large prospective cohort study conducted by Ye and Kang et al and published in JAMA Network Open found that, after adjusting for familial and other cancer-related factors, interstitial lung disease (ILD) was associated with an increased risk of developing most histologic subtypes of lung cancer....

Lung Cancer

Does Exposure to Wildfire-Dominated, Inhalable, Fine Particulate Matter Impact Survival in NSCLC?

Higher ambient exposure to a type of inhalable, fine particulate matter was found to be associated with an increased risk of cancer-related death for patients who were diagnosed with non–small cell lung cancer (NSCLC) while living in California—a state where wildfires are becoming more prevalent,...

Lung Cancer

NSCLC Trial Shows Radiation May Overcome Primary Resistance to Pembrolizumab

The addition of radiation may be able to surmount resistance to immunotherapy for some more immunologically “cold” tumors, as suggested by the findings of a study focused on the immunomodulatory effects of radiation in non–small cell lung cancers (NSCLCs). The research was recently published in...

Lung Cancer

Final Overall Survival Analysis of FLAURA2: Osimertinib Plus Chemotherapy in EGFR-Mutant NSCLC

Positive results from the final overall survival analysis of the phase III FLAURA2 trial showed that osimertinib (a third-generation, irreversible EGFR tyrosine kinase inhibitor) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically...

Lung Cancer

New Guidelines on Comprehensive Biomarker Testing of Bronchoscopic Biopsies

Linear endobronchial guided sampling of accessible mediastinal lesions is well established as a first-choice modality for lung cancer mediastinal staging. Parenchymal lung lesions, however, are routinely accessed by either a percutaneous (CT-guided) or a bronchoscopic approach. There have been few...

Lung Cancer

Phase II Trial Supports SRT as Alternative to WBRT in SCLC

Patients with small cell lung cancer (SCLC) that has metastasized to the brain were safely and successfully treated with targeted stereotactic radiation (SRT) rather than whole-brain radiation therapy (WBRT) in a phase II trial, demonstrating the practicality of a less-invasive approach for...

Lung Cancer

Outcomes With Perioperative Immunotherapy in Resectable NSCLC

In a retrospective cohort study reported in JAMA Network Open, Desai et al examined survival outcomes with the addition of immunotherapy to neoadjuvant or adjuvant chemotherapy in patients with resectable non–small cell lung cancer (NSCLC). Study Details The study involved data from the Flatiron...

lung cancer

Case 3: Newly Diagnosed Limited-Stage Small Cell Lung Cancer

This is Part 3 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss treatment of newly diagnosed limited-stage small cell lung cancer (SCLC). The patient is a 69-year-old woman who presents to an outside hospital with increased swelling in her neck and face, hoarseness, and dyspnea. She is transferred to a cancer institute after a computed tomography identifies a large mediastinal mass with scattered nodules in both lungs. Positron-emission tomography reveals uptake in the mediastinal mass, but no distant metastases, and her brain MRI is clear. Endobronchial ultrasound confirms SCLC, and she is diagnosed with limited-stage SCLC with superior vena cava syndrome. In the conversation that follows, the faculty emphasize the importance of rapid initiation of systemic therapy in patients with symptomatic limited-stage disease, the role of prophylactic cranial irradiation, and the promising impact of immunotherapy with durvalumab. They also discuss emerging treatments like tarlatamab and lurbinectedin.

lung cancer

Case 2: Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

This is Part 2 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss the treatment of newly diagnosed extensive-stage small cell lung cancer (SCLC). The patient is a 66-year-old man who presents with neck swelling. A computed tomography scan reveals a right upper lobe lung mass, mediastinal lymphadenopathy, and liver lesions. He has experienced weight loss but no dyspnea or hemoptysis. Endobronchial ultrasound reveals SCLC, and his brain MRI is clear. He is diagnosed with extensive-stage disease and is currently hospitalized.   In the conversation that follows, the faculty discuss the initial management of patients with SCLC who are hospitalized, stressing the importance of rapid initiation of systemic therapy. They review standard first-line immunotherapy options such as durvalumab or atezolizumab combined with platinum/etoposide, as well as the potential role of maintenance lurbinectedin and emerging agents such as tarlatamab.

lung cancer

Case 1: Relapsed Small Cell Lung Cancer

This is Part 1 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss the treatment of relapsed small cell lung cancer (SCLC). The patient is a 62-year-old woman who presents to an outside hospital with low back pain following a motor vehicle accident. Imaging reveals multiple lytic lesions and a mass in the left lower lung lobe, leading to a diagnosis of extensive-stage small cell lung cancer (SCLC). She receives four cycles of carboplatin, etoposide, and atezolizumab, achieving a near complete response, and then transfers her care to a local oncologist for maintenance therapy. After several months, she returns to the hospital with worsening back pain and dyspnea and is found to have a large pleural effusion and a regrowth of the mass. Cytology confirms the recurrence of SCLC.   In the conversation that follows, the faculty discuss the unique challenges that SCLC presents in emergency settings, the role of maintenance immunotherapy, whether rechallenge with platinum/etoposide is appropriate, and the importance of tailoring treatment strategies to individual patient needs.

Lung Cancer
Immunotherapy

Corticosteroids May Limit Efficacy of Immunotherapy in Patients With NSCLC

Corticosteroids, which are commonly prescribed to alleviate cancer-related symptoms in patients with non–small cell lung cancer (NSCLC) treated with immunotherapy, may be the reason certain immunotherapies fail in treating the disease, according to new research published by Polyakov et al in Cancer ...

Lung Cancer

Air Pollution Linked to Distinct Genomic Signatures in Lung Cancers Among Never-Smokers

A large analysis of the mutational processes of lung cancers in never-smoker patients showed that exposure to fine-particulate air pollution was strongly associated with increased genomic changes, including in cancer-driving and cancer-promoting genetic mutations. Findings from the whole-genome...

Lung Cancer

FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sunvozertinib (Zegfrovy), a selective EGFR tyrosine kinase inhibitor, for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an...

Lung Cancer

HER3-DXd in NSCLC Without EGFR-Activating Mutations

As reported in the Journal of Clinical Oncology by Steuer et al, findings in a cohort of a phase I trial indicated activity of the HER3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) in patients with advanced squamous or nonsquamous non–small cell lung cancer (NSCLC) without a...

Advertisement

Advertisement

Advertisement